share_log

賽生藥業：(1) SILVER PEGASUS INVESTMENT LIMITED 建議（根據公司法第86條）以協議安排方式 將賽生藥業控股有限公司私有化 (2) 建議撤銷賽生藥業控股有限公司的上市地位 (3) 有關存續安排的特定交易 - 延遲寄發計劃文件

SCICLONE PHARMA: (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY OF A SCHEME OF ARRANGEMENT (UNDER SECTION 86 OF THE COMPANIES ACT) (2) PROPOSED WITHDRAWAL OF LISTING OF SCICLONE PHARMACEUTICALS

Hong Kong Stock Exchange ·  Apr 18 04:31
Summary by Moomoo AI
賽生藥業控股有限公司（「賽生藥業」）及Silver Pegasus Investment Limited（「要約人」）於2024年4月18日發布聯合公告，宣布要約人建議根據公司法第86條以協議安排方式將賽生藥業私有化，並撤銷其上市地位。原定計劃文件應於2024年4月18日或之前刊發，但由於需配合大法院時間表及落實計劃文件，執行人員已表示有意同意將期限延長至2024年5月31日。計劃僅會於法院會議獲批准後生效，股東及潛在投資者應謹慎行事，因建議、計劃及購股權要約的實行須待條件達成或獲豁免後方可作實。董事會成員對公告內容的準確性承擔責任，確認經審慎考慮後所表達的意見無遺漏事實，足以令公告所載任何陳述產生誤導。
賽生藥業控股有限公司（「賽生藥業」）及Silver Pegasus Investment Limited（「要約人」）於2024年4月18日發布聯合公告，宣布要約人建議根據公司法第86條以協議安排方式將賽生藥業私有化，並撤銷其上市地位。原定計劃文件應於2024年4月18日或之前刊發，但由於需配合大法院時間表及落實計劃文件，執行人員已表示有意同意將期限延長至2024年5月31日。計劃僅會於法院會議獲批准後生效，股東及潛在投資者應謹慎行事，因建議、計劃及購股權要約的實行須待條件達成或獲豁免後方可作實。董事會成員對公告內容的準確性承擔責任，確認經審慎考慮後所表達的意見無遺漏事實，足以令公告所載任何陳述產生誤導。
Sai Sai Pharmaceutical Holdings Limited (“Sai Sai Pharma”) and Silver Pegasus Investment Limited (the “Contracting Party”) issued a joint announcement on 18 April 2024 announcing that the Contractors propose to privatize Caisang Pharmaceuticals under a contractual arrangement under Section 86 of the Companies Act and withdraw its listed status. The original plan document should be published on or before 18 April 2024, but due to the need to comply with the High Court timetable and implementation plan documents, the executors have agreed to extend the period until 31 May 2024. The Plan will only take effect after approval by the Court of Session. Shareholders and potential investors should exercise caution as the implementation of the Proposals, Plans and Share Option Agreements is conditional upon or waived. The members of the Board are responsible for the accuracy of the contents of the Announcement and to ensure that the opinions expressed after careful consideration are not omissions sufficient to mislead any statements in the Announcement.
Sai Sai Pharmaceutical Holdings Limited (“Sai Sai Pharma”) and Silver Pegasus Investment Limited (the “Contracting Party”) issued a joint announcement on 18 April 2024 announcing that the Contractors propose to privatize Caisang Pharmaceuticals under a contractual arrangement under Section 86 of the Companies Act and withdraw its listed status. The original plan document should be published on or before 18 April 2024, but due to the need to comply with the High Court timetable and implementation plan documents, the executors have agreed to extend the period until 31 May 2024. The Plan will only take effect after approval by the Court of Session. Shareholders and potential investors should exercise caution as the implementation of the Proposals, Plans and Share Option Agreements is conditional upon or waived. The members of the Board are responsible for the accuracy of the contents of the Announcement and to ensure that the opinions expressed after careful consideration are not omissions sufficient to mislead any statements in the Announcement.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more